How it supports desire
PT-141
Acts on melanocortin receptors within the brain to support sexual desire, arousal responsiveness, and sensitivity independent of blood flow mechanisms.
Fast-dissolving compounded PT-141 strips designed to support sexual response and arousal through brain signaling rather than blood-flow-focused mechanisms.
A licensed provider will review your answers
and personalize your care.
No waiting room. No awkward conversation
If approved,
your medication is shipped directly to your door in discreet packaging with free shipping.
Have questions?
Our clinical team is here for you
with unlimited messaging and check-ins throughout your care journey.

Everything you'd want to know before starting.
PT-141 is a name commonly used for bremelanotide, a prescription peptide. An FDA-approved bremelanotide product, Vyleesi®, is available as a subcutaneous injection for certain premenopausal women with acquired, generalized HSDD. If PT-141 is provided in a compounded formulation, that compounded product is not FDA-approved and should not be represented as Vyleesi.
The active ingredient may be the same, but the products are not necessarily the same. Vyleesi is the FDA-approved bremelanotide injection, with a specific dose, delivery system, indication, and prescribing information. A compounded PT-141 preparation has not undergone the same FDA premarket review for safety, effectiveness, or quality.
HSDD stands for hypoactive sexual desire disorder. The Vyleesi label describes its approved population as premenopausal women with acquired, generalized low sexual desire that causes significant distress or interpersonal difficulty and is not better explained by another medical or psychiatric condition, relationship problem, medication, or drug. Whether HSDD applies to an individual requires clinical evaluation.
The FDA-approved bremelanotide product Vyleesi is not indicated for postmenopausal women. Compounded PT-141 formulations are not FDA-approved products, so the Vyleesi indication should not be applied to them as though they were equivalent. Whether any prescription treatment may be appropriate after menopause requires an individualized clinician assessment.
No. Sildenafil, commonly associated with Viagra®, is a PDE5 inhibitor, while bremelanotide belongs to a different drug class. The FDA-approved bremelanotide product Vyleesi also has a specific HSDD indication and is explicitly not indicated for enhancing sexual performance. Referring to PT-141 as “female Viagra” can therefore be misleading.
Share your complete health history, medications, and cardiovascular and blood-pressure history. The FDA-approved Vyleesi label lists uncontrolled hypertension and known cardiovascular disease as contraindications and contains additional warnings and precautions. A clinician can determine which considerations are relevant to the specific formulation being prescribed.
Yes. PT-141/bremelanotide is offered as a prescription treatment. Through AmalfiDuo, you complete a private online health evaluation, and a licensed clinician reviews your information to determine whether treatment may be appropriate.
%20(1).webp)

Answer a few private questions and receive a personalized treatment recommendation from a licensed provider.